Predictive Value of Tumor-infiltrating Lymphocytes for Neoadjuvant Therapy Response in Triple-negative Breast Cancer: A Systematic Review and Meta-analysis

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2024 Jul 29

PMID 39071463

Authors

Hai-Kuan Sun

Wen-Long Jiang

Shi-Lei Zhang

Peng-Cheng Xu

Li-Min Wei

Jiang-Bo Liu

Affiliations

Soon will be listed here.

Abstract

Background: The association between tumor-infiltrating lymphocyte (TIL) levels and the response to neoadjuvant therapy (NAT) in patients with triple-negative breast cancer (TNBC) remains unclear.

Aim: To investigate the predictive potential of TIL levels for the response to NAT in TNBC patients.

Methods: A systematic search of the National Center for Biotechnology Information PubMed database was performed to collect relevant published literature prior to August 31, 2023. The correlation between TIL levels and the NAT pathologic complete response (pCR) in TNBC patients was assessed using a systematic review and meta-analysis. Subgroup analysis, sensitivity analysis, and publication bias analysis were also conducted.

Results: A total of 32 studies were included in this meta-analysis. The overall meta-analysis results indicated that the pCR rate after NAT treatment in TNBC patients in the high TIL subgroup was significantly greater than that in patients in the low TIL subgroup (48.0% 27.7%) (risk ratio 2.01; 95% confidence interval 1.77-2.29; < 0.001, = 56%). Subgroup analysis revealed that the between-study heterogeneity originated from differences in study design, TIL level cutoffs, and study populations. Publication bias could have existed in the included studies. The meta-analysis based on different NAT protocols revealed that all TNBC patients with high levels of TILs had a greater rate of pCR after NAT treatment in all protocols (all ≤ 0.01), and there was no significant between-protocol difference in the statistics among the different NAT protocols ( = 0.29). Additionally, sensitivity analysis demonstrated that the overall results of the meta-analysis remained consistent when the included studies were individually excluded.

Conclusion: TILs can serve as a predictor of the response to NAT treatment in TNBC patients. TNBC patients with high levels of TILs exhibit a greater NAT pCR rate than those with low levels of TILs, and this predictive capability is consistent across different NAT regimens.

References

Abuhadra N, Sun R, Yam C, Rauch G, Ding Q, Lim B . Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023; 15(13). PMC: 10339918. DOI: 10.3390/cancers15133275. View

Rangan R, Kanetkar S, Bhosale S, Mane D, Patil N, Gudur R . Assessment of Intratumoural and Stromal Infiltrating Lymphocytes In The Various Subtypes of Breast Carcinoma Patients who have Received Neoadjuvant Chemotherapy. Asian Pac J Cancer Prev. 2023; 24(7):2347-2352. PMC: 10676494. DOI: 10.31557/APJCP.2023.24.7.2347. View

Herrero-Vicent C, Guerrero A, Gavila J, Gozalbo F, Hernandez A, Sandiego S . Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. Ecancermedicalscience. 2017; 11:759. PMC: 5574654. DOI: 10.3332/ecancer.2017.759. View

Hida A, Watanabe T, Sagara Y, Kashiwaba M, Sagara Y, Aogi K . Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer. Breast Cancer Res Treat. 2019; 178(2):283-294. DOI: 10.1007/s10549-019-05390-x. View

Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J . Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. NPJ Breast Cancer. 2021; 7(1):9. PMC: 7870853. DOI: 10.1038/s41523-021-00219-7. View

Lusho S, Durando X, Mouret-Reynier M, Kossai M, Lacrampe N, Molnar I . Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients. Front Oncol. 2021; 11:678315. PMC: 8331686. DOI: 10.3389/fonc.2021.678315. View

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

10.

Heckler M, Ali L, Clancy-Thompson E, Qiang L, Ventre K, Lenehan P . Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discov. 2021; 11(10):2564-2581. PMC: 8487897. DOI: 10.1158/2159-8290.CD-20-1540. View

11.

Wang Y, Brodsky A, Xiong J, Lopresti M, Yang D, Resnick M . Stromal Clusterin Expression Predicts Therapeutic Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer. Clin Breast Cancer. 2017; 18(3):e373-e379. DOI: 10.1016/j.clbc.2017.08.007. View

12.

Cerbelli B, Botticelli A, Pisano A, Pernazza A, Campagna D, De Luca A . CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. Virchows Arch. 2019; 476(4):569-576. DOI: 10.1007/s00428-019-02722-6. View

13.

Zhang L, Wang X, Zhang S . Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer. Hum Pathol. 2018; 80:47-54. DOI: 10.1016/j.humpath.2018.05.024. View

14.

Kolberg-Liedtke C, Feuerhake F, Garke M, Christgen M, Kates R, Grischke E . Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial. Breast Cancer Res. 2022; 24(1):58. PMC: 9438265. DOI: 10.1186/s13058-022-01552-w. View

15.

Abdelrahman A, Rashed H, MostafaToam , Omar A, Abdelhamid M, Matar I . Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy. Ann Diagn Pathol. 2020; 51:151676. DOI: 10.1016/j.anndiagpath.2020.151676. View

16.

Dong X, Liu C, Yuan J, Wang S, Ding N, Li Y . Prognostic Roles of Neutrophil-to-Lymphocyte Ratio and Stromal Tumor-Infiltrating Lymphocytes and Their Relationship in Locally Advanced Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy. Breast Care (Basel). 2021; 16(4):328-334. PMC: 8436630. DOI: 10.1159/000509498. View

17.

Abuhadra N, Sun R, Litton J, Rauch G, Yam C, Chang J . Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022; 14(5). PMC: 8909018. DOI: 10.3390/cancers14051323. View

18.

Bianchini G, De Angelis C, Licata L, Gianni L . Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2021; 19(2):91-113. DOI: 10.1038/s41571-021-00565-2. View

19.

Sharma P, Kimler B, ODea A, Nye L, Wang Y, Yoder R . Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP). Clin Cancer Res. 2020; 27(4):975-982. PMC: 7887017. DOI: 10.1158/1078-0432.CCR-20-3646. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View